Emicizumab for the treatment of acquired hemophilia A | 合法藥品大搜索

Read More

由 P Knoebl 著作 · 2021 · 被引用 18 次 — For hemostatic treatment, bypassing agents and human or porcine FVIII are currently standard of care. Emicizumab is a bispecific, FVIII-mimetic ... Read More

由 ZY Zhou 著作 · 2020 · 被引用 2 次 — Background: Hemophilia A (HA) can result in bleeding events because of low or absent clotting factor VIII (FVIII). Read More

由 J Oldenburg 著作 · 2017 · 被引用 546 次 — Emicizumab prophylaxis was associated with a significantly lower rate of bleeding events than no prophylaxis among participants with ... Read More

2021年1月21日 — Emicizumab is a bispecific, FVIII-mimetic therapeutic antibody that has considerably reduced the annualized bleeding rates in congenital ... Read More

由 M Franchini 著作 · 2019 · 被引用 32 次 — In a long-term primate model of acquired haemophilia A, the same authors showed that weekly subcutaneous doses of emicizumab (initially 4 mg/kg ... Read More

2020年6月5日 — What is the role of emicizumab in the treatment of hemophilia A? ... Emicizumab is a first-in-class bispecific monoclonal antibody that performs ... Read More

由 J Mahlangu 著作 · 2018 · 被引用 300 次 — Emicizumab is a bispecific monoclonal antibody that bridges activated factor IX and factor X to replace the function of missing activated factor ... Read More

Learn about HEMLIBRA® (emicizumab-kxwh), a hemophilia A treatment approved for people with hemophilia A with or without factor VIII inhibitors. Read More